Eldridge Industries to Launch Eldridge, an Asset Management and Insurance Holding Company with $74 billion in AUM
5.12.2024 12:30:00 CET | Business Wire | Press release
Today, Eldridge Industries announced plans to launch Eldridge, an asset management and insurance holding company with approximately $74 billion in assets under management. Eldridge will be wholly owned by Eldridge Industries and consist of two divisions: Eldridge Capital Management and Eldridge Wealth Solutions.
Eldridge Capital Management will focus on four investment strategies – corporate credit, GP solutions, real estate credit, and sports, media, and entertainment – and will conduct business under the Eldridge brand. Eldridge Wealth Solutions, an insurance and retirement solutions platform, will be comprised of Eldridge’s wholly owned insurance companies, Security Benefit and Everly Life.
Eldridge will be managed by a newly formed Executive Committee, chaired by Todd Boehly, Chairman and CEO and controlling shareholder of Eldridge Industries. Mr. Boehly, in his capacity as Chairman of Eldridge’s Executive Committee, will be involved with strategic oversight and partnerships of both Eldridge Capital Management and Eldridge Wealth Solutions.
“Eldridge will bring together decades of collective experience, world-class structuring, proprietary origination expertise, and differentiated approaches to capitalize on what we believe to be the most attractive opportunity set in quite some time, and we are excited to enter this next chapter of growth,” said Mr. Boehly. “We are confident that the firm will provide the highest level of service and generate new, compelling investment opportunities.”
Tony Minella, Eldridge Industries Co-founder and President, who has worked alongside Mr. Boehly for approximately twenty-five years, will lead Eldridge Capital Management as Chief Executive Officer. Todd Gilbert and Nicholas Sandler will serve as Co-Presidents of Eldridge Capital Management.
Eldridge Wealth Solutions will be led by Doug Wolff as Chief Executive Officer and Joseph Wittrock as Chief Investment Officer.
Existing Eldridge Industries businesses and teams, including Maranon Capital, Security Benefit’s Corporate Credit team, Stonebriar Commercial Finance’s Investment team, Cain International’s Real Estate Credit team, and Panagram Structured Asset Management, will integrate under Eldridge Capital Management and be rebranded as follows:
- Eldridge Corporate Credit will be co-led by Jeffrey Forlizzi and Nicholas Sandler and invest across a broad spectrum of private, asset-backed, opportunistic, and structured credit. The strategy will thoroughly underwrite downside scenarios to provide a margin of safety and utilize a rigorous, fundamental-driven, and value-oriented approach emphasizing deep investment research while balancing company, industry, and macro risks.
- Eldridge GP Solutions will be led by David Lee and invest in market-leading businesses through attractive middle-market GP-led transactions, including GP-led single-asset continuation vehicles, direct GP-led transactions, and provide other comprehensive capital and liquidity solutions to GPs.
- Eldridge Real Estate Credit will be led by John Cole andtake a disciplined, patient approach to investment in real estate credit opportunities across the U.S., U.K., and Europe by investing in construction, bridge, and special situation opportunities across the capital structure, primarily in gateway cities with best-in-class sponsors and assets.
- Eldridge Sports, Media, and Entertainment will be led by Jeff Wilbur and make investments in private companies that create and own premium intellectual property that can be distributed and monetized in multiple ways within the sports, media, and entertainment sectors.
Eldridge will have offices in New York, Greenwich, Beverly Hills, Chicago, Dallas, Atlanta, Overland Park, Des Moines, Topeka, London, and Abu Dhabi.
The transaction is expected to close in January 2025.
About Eldridge Industries
Eldridge Industries invests in businesses across the Insurance, Asset Management, Technology, Mobility, Sports & Gaming, Media & Music, Real Estate, and Consumer landscapes. The firm seeks to build and grow businesses led by proven management teams that have demonstrated leadership and experience to scale an enterprise. Eldridge Industries has offices in Miami, Greenwich, Beverly Hills, New York, and London. To learn more about Eldridge Industries, please visit eldridge.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205643580/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release
Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release
Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom